Richard A. Peterson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Richard A. Peterson has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
David L. Krull
2 shared publicationsChristopher T. Winkelmann
Merck Research Laboratories, West Point, PA, USA
1 shared publicationG. Allan Johnson
Duke University, Durham, NC, USA
1 shared publicationH. Roger Brown
1 shared publicationKathy L. Gabrielson
Johns Hopkins School of Medicine, Baltimore MD, USA
1 shared publicationLeroy Butler
Molecular and Ultrastructural Pathology Group, Safety Assessment, GlaxoSmithKline, Research Triangle Park, North Carolina, USA
1 shared publication
Latest Publications
- 5 January 2012
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 40 (2) , 186-204
Regulatory T-Cells: Diverse Phenotypes Integral to Immune Homeostasis and Suppression
Regulatory T-cells (TREG) are diverse populations of lymphocytes that regulate the adaptive immune response in higher vertebrates. TREG delete autoreactive T-cells, induce tolerance, and dampen inflammation. TREG cell deficiency in humans (i.e., IPEX [Immunodysregulation, Polyendocrinopathy and Enteropathy, X-linked syndrome]) and animal models (e.g., “Scurfy” mouse) is associated with multisystemic autoimmune disease. TREG in humans and laboratory animal species are similar in type and regulatory function. A molecular marker of and the cell lineage specification factor for TREG is FOXP3, a forkhead box transcription factor. CD4+ TREG are either natural (nTREG), which are thymus-derived CD4+CD25+FOXP3+ T-cells, or inducible (i.e., Tr1 cells that secrete IL-10, Th3 cells that secrete TGF-β and IL-10, and Foxp3+ Treg). The proinflammatory Th17 subset has been a major focus of research. TH17 CD4+ effector T-cells secrete IL-17, IL-21, and IL-22 in autoimmune and inflammatory disease, and are dynamically balanced with TREG cell development. Other lymphocyte subsets with regulatory function include: inducible CD8+ TREG, CD3+CD4−CD8− TREG (double-negative), CD4+Vα14+ (NKTREG), and γδ T-cells. TREG have four regulatory modes of action: secretion of inhibitory cytokines (e.g., IL-10 and TGF-β), granzyme-perforin-induced apoptosis of effector lymphocytes, depriving effector T-cells of cytokines leading to apoptosis, or inhibition of dendritic cell function. The role of TREG in mucosal sites, inflammation/infection, pregnancy, and cancer as well as a review of TREG as a modulatory target in drug development will be covered.
- 5 January 2012
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 40 (2) , 186-204
Regulatory T-Cells: Diverse Phenotypes Integral to Immune Homeostasis and Suppression
Regulatory T-cells (TREG) are diverse populations of lymphocytes that regulate the adaptive immune response in higher vertebrates. TREG delete autoreactive T-cells, induce tolerance, and dampen inflammation. TREG cell deficiency in humans (i.e., IPEX [Immunodysregulation, Polyendocrinopathy and Enteropathy, X-linked syndrome]) and animal models (e.g., “Scurfy” mouse) is associated with multisystemic autoimmune disease. TREG in humans and laboratory animal species are similar in type and regulatory function. A molecular marker of and the cell lineage specification factor for TREG is FOXP3, a forkhead box transcription factor. CD4+ TREG are either natural (nTREG), which are thymus-derived CD4+CD25+FOXP3+ T-cells, or inducible (i.e., Tr1 cells that secrete IL-10, Th3 cells that secrete TGF-β and IL-10, and Foxp3+ Treg). The proinflammatory Th17 subset has been a major focus of research. TH17 CD4+ effector T-cells secrete IL-17, IL-21, and IL-22 in autoimmune and inflammatory disease, and are dynamically balanced with TREG cell development. Other lymphocyte subsets with regulatory function include: inducible CD8+ TREG, CD3+CD4−CD8− TREG (double-negative), CD4+Vα14+ (NKTREG), and γδ T-cells. TREG have four regulatory modes of action: secretion of inhibitory cytokines (e.g., IL-10 and TGF-β), granzyme-perforin-induced apoptosis of effector lymphocytes, depriving effector T-cells of cytokines leading to apoptosis, or inhibition of dendritic cell function. The role of TREG in mucosal sites, inflammation/infection, pregnancy, and cancer as well as a review of TREG as a modulatory target in drug development will be covered.
- Open Access
- 8 December 2010
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 39 (1) , 267-272
Continuing Education Course #1
The continuing education course “Non-Invasive Imaging as a Problem-Solving Tool and Translational Biomarker Strategy in Toxicologic Pathology” provided a thorough overview of commonly used imaging modalities and the logistics required for integration of small animal imaging into toxicologic pathology. Non-invasive imaging (NIN) is gaining acceptance as an important modality in toxicologic pathology. This technology allows nonterminal, time-course evaluation of functional and morphologic endpoints and can be used to translate biomarkers between preclinical animal models and human patients. NIN can support drug development as well as basic research in academic or industrial environments. An initial overview of theoretical principles was followed by focused presentations on magnetic resonance imaging (MRI)/magnetic resonance microscopy (MRM), positron emission tomography (PET)/single proton emission computed tomography (SPECT), ultrasonography (US, primarily focused on echocardiography), optical (bioluminescent) imaging, and computed tomography (CT). The choice of imaging modality will depend on the research question and the needed resolution.
- 8 December 2010
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 39 (1) , 267-272
Open AccessContinuing Education Course #1
The continuing education course “Non-Invasive Imaging as a Problem-Solving Tool and Translational Biomarker Strategy in Toxicologic Pathology” provided a thorough overview of commonly used imaging modalities and the logistics required for integration of small animal imaging into toxicologic pathology. Non-invasive imaging (NIN) is gaining acceptance as an important modality in toxicologic pathology. This technology allows nonterminal, time-course evaluation of functional and morphologic endpoints and can be used to translate biomarkers between preclinical animal models and human patients. NIN can support drug development as well as basic research in academic or industrial environments. An initial overview of theoretical principles was followed by focused presentations on magnetic resonance imaging (MRI)/magnetic resonance microscopy (MRM), positron emission tomography (PET)/single proton emission computed tomography (SPECT), ultrasonography (US, primarily focused on echocardiography), optical (bioluminescent) imaging, and computed tomography (CT). The choice of imaging modality will depend on the research question and the needed resolution.
- 1 August 2010
- Published by Bentham Science Publishers Ltd. in Drug Metabolism Letters
- Vol. 4 (3) , 180-184
Morphologic Characterization of PhoenixBio® (uPA+/+/SCID) Humanized Liver Chimeric Mouse Model
Abstract: Morphological evaluation of humanized chimeric mouse livers from the PhoenixBio® (uPA+/+/SCID) mouse model show robust replacement and expansion with human hepatocytes, however areas of human hepatocytes had prominent steatosis and a variable lack of sinusoids which was consistent with decreased hepatocellular perfusion and lacked bile canalicular formation between human and mouse hepatocytes.
- 1 August 2010
- Published by Bentham Science Publishers Ltd. in Drug Metabolism Letters
- Vol. 4 (3) , 180-184
Morphologic Characterization of PhoenixBio® (uPA+/+/SCID) Humanized Liver Chimeric Mouse Model
Abstract: Morphological evaluation of humanized chimeric mouse livers from the PhoenixBio® (uPA+/+/SCID) mouse model show robust replacement and expansion with human hepatocytes, however areas of human hepatocytes had prominent steatosis and a variable lack of sinusoids which was consistent with decreased hepatocellular perfusion and lacked bile canalicular formation between human and mouse hepatocytes.
- Open Access
- 1 January 2008
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 36 (1) , 117-132
Applications of Laser Scanning Cytometry in Immunohistochemistry and Routine Histopathology
Laser scanning cytometry (LSC) is a powerful tool for qualitative and quantitative analysis of tissue sections in preclinical drug development. LSC combines the strengths of flow cytometry with tissue architecture retention. This technology has been used predominantly with immunofluorescent techniques on cell culture and tissue sections, but recently LSC has shown promise in evaluating chromogenic immunohistochemistry (IHC) and histochemical products in paraffin-embedded and/or frozen tissue sections. Inverted light scatter measurements or a combination of inverted scatter and fluorescence allows automated determination of cell/nuclear counts (e.g., proliferation labeling indices), cell area (e.g., cellular hypertrophy), stromal elements, and labeling intensity (e.g., cytoplasmic/organellar proteins) in chromogen-labeled IHC or histochemical stained sections that correlates well with standard manual quantification methods. Segmentation with autofluorescence or dual immunolabeling facilitates capture of labeling data from specific cell populations. LSC evaluation of HE-stained sections is accomplished using autofluorescence/eosin fluorescence and inverse scatter. A standardized fluorescent approach with archivability, a lack of fluorescence quenching (photobleaching), and amenability to evaluation of multiple markers in a section has been demonstrated using Qdot® nanocrystals. Examples of LSC use in chromogenic IHC, routine histopathology, and Qdot® labeling will be reviewed, and advantages and disadvantages of this technology will be discussed.
- 1 January 2008
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 36 (1) , 117-132
Open AccessApplications of Laser Scanning Cytometry in Immunohistochemistry and Routine Histopathology
Laser scanning cytometry (LSC) is a powerful tool for qualitative and quantitative analysis of tissue sections in preclinical drug development. LSC combines the strengths of flow cytometry with tissue architecture retention. This technology has been used predominantly with immunofluorescent techniques on cell culture and tissue sections, but recently LSC has shown promise in evaluating chromogenic immunohistochemistry (IHC) and histochemical products in paraffin-embedded and/or frozen tissue sections. Inverted light scatter measurements or a combination of inverted scatter and fluorescence allows automated determination of cell/nuclear counts (e.g., proliferation labeling indices), cell area (e.g., cellular hypertrophy), stromal elements, and labeling intensity (e.g., cytoplasmic/organellar proteins) in chromogen-labeled IHC or histochemical stained sections that correlates well with standard manual quantification methods. Segmentation with autofluorescence or dual immunolabeling facilitates capture of labeling data from specific cell populations. LSC evaluation of HE-stained sections is accomplished using autofluorescence/eosin fluorescence and inverse scatter. A standardized fluorescent approach with archivability, a lack of fluorescence quenching (photobleaching), and amenability to evaluation of multiple markers in a section has been demonstrated using Qdot® nanocrystals. Examples of LSC use in chromogenic IHC, routine histopathology, and Qdot® labeling will be reviewed, and advantages and disadvantages of this technology will be discussed.